Our findings indicate that KS18 significantly diminishes Mcl-1 expression triggered by venetoclax and ABT-737 in bortezomib-resistant MM cells, thereby addressing a critical resistance mechanism associated with Bcl-2/Bcl-xL inhibitors. Here, BCL2L1 is linked to Miyoshi myopathy.